Werfen increases sales by over 13% and reaffirms its global leadership in in vitro diagnostics

Food and Healthcare Press Releases Friday April 27, 2018 13:44
BARCELONA, Spain--27 Apr--PRNewswire/InfoQuest
Werfen, a global leader in healthcare and life sciences, achieves revenues of 1,337 million euros in 2017, a 13.3% increase against 2016.

Excluding the impact of recent acquisitions, sales from organic growth grew by 4.6%. With these results, Werfen continues to be a global leader in in vitro diagnostics, providing innovative solutions for hospitals and commercial laboratories with the aim of improving patient care and reducing healthcare costs.

Werfen is reporting net profit of 160 million euros for 2017, representing a 15.1% increase over 2016. EBITDA has grown to 284 million euros, representing an increase of 6%.

Werfen is performing very well in its main areas of expertise. Hemostasis has an increase of 7.5%, Autoimmunity has grown by 6.6%, while the new business line, Acute Care Diagnostics, has achieved organic growth of 4.8%.

The expansion of the product portfolio has been one of the main causes of the increase in sales following the acquisitions of Tem and Accriva Diagnostics. As a result, the Critical Care business line has evolved into Acute Care Diagnostics, providing comprehensive solutions for emergency care, traumatology, and operating rooms.

Werfen has strengthened its presence in all regions, especially in China, where sales have achieved a 21% increase against 2016. Currently, Asia-Pacific accounts for 16% of total revenues.

Western Europe is the strongest market, bringing in 42% of Werfen revenues, while North America accounted for 26%. The areas with the greatest potential for growth are Latin America and EEMEAI (Eastern Europe, Middle East, Africa and India), each of which generated 8% of total sales.

The objectives set for 2018 are to further strengthen the main areas of expertise, to continue to grow in China, and to boost expansion in the emerging markets of Latin America, Asia-Pacific and EEMEAI.

WERFEN is one of the leading global corporations in IVD through its companies Instrumentation Laboratory (Hemostasis, Acute Care Diagnostics), Inova Diagnostics (Autoimmunity) and Biokit (OEM, infectious disease serology); in addition to clinical software and chemical chemistry. Werfen is also involved in medical devices through its company Leventon and other entities for distribution.

Werfen has a direct presence in around 30 countries and more than 100 territories through distributors. It has a team of over 5,000 people, and its R&D and manufacturing activities are carried out in the United States and Europe.


Latest Press Release

WCG (WIRB-Copernicus Group) Clinical Services Division Opens Office in Japan

WCG(TM) (WIRB-Copernicus Group(R)) Clinical Services Division, the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research, today announced the opening of the company's new office in Tokyo, Japan....

Head-to-Head Trial Shows Refixia(R) Achieves Greater Total Factor IX Exposure in People With Haemophilia B Than Recombinant Factor IX-Fc Fusion Protein

Adults with haemophilia B who received a single dose Refixia(R) (nonacog beta pegol; N9-GP) achieved greater total factor IX exposure than those treated with rFIXFc (recombinant factor IX-Fc fusion protein). The head-to-head paradigm7 trial also observed...

NovoEight(R) Maintains Potency When Stored at 40?C Offering People With Haemophilia A Increased Flexibility in Their Daily Lives

A new long term stability study has shown that haemophilia A treatment NovoEight(R) (turoctocog alfa) remains potent after three months exposure to temperatures of 40ºC.[1] The results were presented today at the WFH 2018 World Congress in Glasgow,...

The Mall Shopping Center and Government Savings Bank Co-host The Mall Health Beauty Expo 2018

The Mall Shopping Center, Government Savings Bank, leading hospitals and health institutions are co-hosting an annual grand event, "The Mall Health & Beauty Expo 2018" on June 28 – July 4, 2018 at the Grand Hall, G Floor, The Mall Bangkapi....

Merck Data at ASCO 2018 to Showcase Progress and Further Optionality of Oncology Pipeline

ASCO Abstract # ERBITUX(R) (cetuximab): 3521, 3534, e15711; avelumab: 9507, 9537, 9090, 9008, 8563, 3057, 4544, e21531, e13603, e18932, e21623, e21620, e21544; tepotinib (c-Met kinase inhibitor): 9082, 9016; M6620 (ATR inhibitor): 2549, e21048; M3814...

Related Topics